Twentyeight Health, founded by Amy Fan from UC Berkeley Haas, was named one of our most disruptive MBA startups of 2020.
Chronus Health, 2018
MBA Founder: Anand Parikh, UC San Diego Rady School of Management
Total Raised: $24 million
Latest Funding Round: $22M series A in Jan 2022
Chronus Health is a portable platform that enables doctors to provide real-time diagnosis treatment based on actual lab results. It can deliver lab results in minutes to improve patient outcomes. In its latest funding round in January 2022, it raised $22 million in Series A with Tarsadia Investments as its lead investor, according to Crunchbase.com.
“Our revolutionary platform is poised to disrupt the clinical lab testing market, which primarily relies on expensive and bulky blood analyzers in central labs,” Parikh, CEO and co-founder of Chronus Health, said in a company press release on the heels of its Series A funding round.
“Our low cost and compact system, which leverages microfluidic and semiconductor technologies, enables real-time diagnostics in multiple clinical settings and is designed to improve time-to-care and outcomes for patients globally.”
Glyphic Biotechnologies, 2021
MBA Founder: Josh Yang, Stanford GSB
Total Raised: $16 million
Latest Funding Round: $2.9M Grant April 2022
Glyphic Biotechnologies is a biotech startup developing single-molecule protein sequencers to fundamentally change biomedical discovery. This platform aims to develop novel therapeutics and diagnostics and, ultimately, a deeper understanding of human biology.
Co-founder Josh Yang, MBA ‘21, met his co-founder through Nucleate Bio which connects founders for new ventures.
“It felt like everyone wanted to do entrepreneurship at the GSB, with so many fellow classmates forming startups with each other. This collaborative culture and entrepreneurial environment made it so that there was no absence of resources and advice, from logistical questions about how to actually start a company to the more nuanced questions of term sheet negotiations,” he told P&Q in 2021 when Glyphic Biotechnologies was named one of our most disruptive MBA startups of the year.
“When I started my fundraising for our Seed round, I received so many warm connections from fellow Stanford GSB classmates, some of which resulted in term sheets from Stanford GSB alums. In this process, the Stanford GSB name and reputation helped open doors and provided a baseline level of credibility when speaking to investors.”
Twentyeight Health, 2018
MBA Founder: Amy Fan, UC Berkeley Haas School of Business
Total Raised: $16 million
Latest Funding Round: $5.1M Seed Oct 2020
Twentyeight Health is a women’s healthcare company with a mission to expand access to reproductive and sexual health for underserved communities, including women of color and women from low-income households. Starting with birth control, Twentyeight Health built an end-to-end platform to provide telemedicine, prescription delivery, and ongoing care. It raised $8.3 million seed funding in its latest round, with Acumen America leading 14 other investors, according to Crunchbase.com.
At Berkeley, Fan met her cofounder, Bruno Van Tuykom, who had led market access in family planning, malaria and HIV at the Gates Foundation.
“We discussed the potential of telemedicine as he shared his experiences in developing markets, where he had seen how telemedicine could overcome lack of infrastructure and stigma to deliver reproductive and sexual health services,” she told Poets&Quants.
“Seeing the situation in the US – where nearly 20 million women live in contraceptive deserts and the maternal mortality rate is 2-times higher for women from low income and 3-times higher for Black women – we wanted to leverage telemedicine to solve the problem of bureaucracy blocking women from getting care.”
Cardiosense, 2020
MBA Founder: Amit Gupta, Northwestern Kellogg School of Management
Total Raised: $15.2 million
Latest Funding Round: $15.1M Series A Dec 2022
Cardiosense is developing a non-invasive, AI powered monitoring platform for the early detection of heart disease. In September, it began enrolling patients in its first nationwide clinical trial to test its technology in detecting early markers to heart failure. It was awarded FDA Breakthrough Device Designation in 2022. The company raised $15.1 million in 2022 from six investors, led by Broadview Ventures and Hatteras Venture Partners, according to Crunchbase.com.
Gupta, founder and CEO, was a 2020 new venture Zell Fellow at Kellogg, a highly competitive accelerator for Kellogg MBAs who either want to create something new or acquire and build upon an existing venture.
NEXT PAGE: MBA Healthcare Startups Moons, Nilo Saúde, EnPlusOne Biosciences, and SiteRx
Questions about this article? Email us or leave a comment below.